Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Benzinga · 1d ago
Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.